Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 9/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13322388 | 0.87 | HSP90AA1 (0.52) | KMT2AALDH1A1SMN1; SMN2MGLLL3MBTL1 | |
| SCHEMBL13466398 | 0.82 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16131141 | 0.82 | ALDH1A1 (0.51) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13086636 | 0.79 | CTSA (0.53) | KMT2AALDH1A1SMN1; SMN2MGLLL3MBTL1 | |
| SCHEMBL18376152 | 0.79 | HPGD (0.64) | KMT2AALDH1A1L3MBTL4L3MBTL3L3MBTL1 | |
| SCHEMBL16131150 | 0.79 | MGLL (0.45) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13466390 | 0.79 | MGLL (0.45) | MGLLTDP1 | |
| SCHEMBL21183229 | 0.79 | MGLL (0.45) | KMT2AMGLL | |
| SCHEMBL12545840 | 0.76 | HPGD (0.70) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL10168906 | 0.76 | KMT2A (0.64) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-9878995-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878995-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | KMT2A 1644/4885MEN1 1719/4885ALDH1A1 2149/4885 |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | KMT2A 1644/4885MEN1 1719/4885ALDH1A1 2149/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | KMT2A 1644/4885MEN1 1719/4885ALDH1A1 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.